New mRNA flu shot passes first safety check in early trial

NCT ID NCT05829356

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times

Summary

This early-stage study tested a new mRNA-based flu vaccine in 159 healthy adults aged 18-49 and 60+. Participants received one injection of the experimental vaccine or a licensed flu shot. The main goals were to check safety and measure the immune response. Results will help decide if the vaccine should move to larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA IMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number : 0360001

    Morayfield, Queensland, 4506, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, 3124, Australia

  • Investigational Site Number : 0360003

    Adelaide, 5000, Australia

  • Investigational Site Number : 0360004

    Herston, Queensland, 4006, Australia

  • Investigational Site Number : 8260001

    London, London, City of, SW10 9NH, United Kingdom

  • Investigational Site Number : 8260002

    Leicester, Leicestershire, LE1 5WW, United Kingdom

  • Investigational Site Number : 8260003

    Sheffield, Sheffield, S10 2JF, United Kingdom

  • Investigational Site Number : 8260004

    London, London, City of, W12 0HS, United Kingdom

Conditions

Explore the condition pages connected to this study.